Clover Health Investments, Corp 8-K, filed May 27, 2022
Clover Health Investments, Corp. (CLOV)
8-K
2022-05-27
For: 2022-05-26
View Original
Added on
April 06, 2026
About this 8-K
Clover Health Investments, Corp filed this 8-K on May 27, 2022, reporting on events of May 26, 2022.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 26, 2022
CLOVER HEALTH INVESTMENTS, CORP.
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction | (Commission File Number) | (IRS Employer | ||||||
of Incorporation) | Identification No.) | |||||||
(Address of Principal Executive Offices) | (Zip Code) | |||||||
Registrant’s Telephone Number, Including Area Code: (201 ) 432-2133
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Trading | ||||||||||||||
Title of each class | Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 26, 2022, Nathaniel S. Turner resigned as a member of the Board of Directors of Clover Health Investments, Corp. ("Clover" or the "Company"). Mr. Turner’s resignation as a director was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.
“It has been an honor to serve as a member of Clover’s Board of Directors for the past six years. I’ve been deeply impressed by the team Clover has brought together and the impact they are making, and I look forward to seeing them continue on their mission to improve every life,” said Turner.
“Nat’s advice, guidance, and support have been invaluable since Clover’s inception. We are immensely grateful for his contributions including being a driving force in the founding of Clover,” said Clover Co-Founder, CEO and Chairman, Vivek Garipalli.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Clover Health Investments, Corp. | ||||||||||||||
| Date: | May 27, 2022 | By: | /s/ Mark C. Herbers | |||||||||||
| Name: | Mark C. Herbers | |||||||||||||
| Title: | Interim Chief Financial Officer | |||||||||||||